Valuation: Exelixis, Inc.

Market Cap 13.48B 11.54B 10.74B 9.9B 18.61B 1,290B 18.91B 127B 49.88B 645B 50.6B 49.5B 2,130B P/E 2026 *
16.8x
P/E 2027 * 14.3x
Enterprise Value 12.73B 10.9B 10.15B 9.36B 17.58B 1,219B 17.87B 120B 47.12B 610B 47.8B 46.76B 2,013B EV / Sales 2026 *
4.99x
EV / Sales 2027 * 4.13x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -
1 day+2.39%
1 week+5.96%
Current month+2.56%
1 month-2.74%
3 months+9.13%
6 months+22.31%
Current year+24.09%
1 week 49.97
Extreme 49.97
54.58
1 month 49.97
Extreme 49.97
56.95
Current year 39.71
Extreme 39.71
57.57
1 year 33.76
Extreme 33.755
57.57
3 years 18.64
Extreme 18.64
57.57
5 years 14.87
Extreme 14.87
57.57
10 years 10.04
Extreme 10.04
57.57
Manager TitleAgeSince
Chief Executive Officer 65 2010-07-21
Director of Finance/CFO 58 2015-07-14
Chief Operating Officer 63 2016-01-31
Director TitleAgeSince
Director/Board Member 70 2004-01-31
Director/Board Member 82 2004-07-31
Chairman 77 1997-12-31
Date Insider Type Main position Quantity % Market Cap.
8/10/26 Sell

Director

-9,812 0.0039%
5/27/26 Free

Director

8,367 0.0033%
2/26/26 Free

General Counsel

23,119 0.0086%
Change 5-day change 1-year change 3-year change Capi.($)
+2.39%+5.96%+44.04%+157.77% 13.16B
-1.90%+2.37%+69.11%+110.88% 73.45B
+0.87%+17.17%+53.05%+95.59% 62.99B
+1.71%-1.44%+2.66%+501.29% 28.05B
-1.40%+4.18%+54.52%+19.60% 25.42B
+21.96%+21.90%+0.51%+2.50% 23.3B
+2.28%+7.98%+42.75%-12.34% 19.45B
0.00%-4.11%+243.99%+423.83% 18.16B
-3.50%-0.95%+17.17%+534.55% 16.53B
+1.72%+0.19%+349.07%+216.38% 12.42B
Average +0.38%+2.32%+87.69%+205.00% 29.29B
Weighted average by Cap. +0.04%+4.14%+69.47%+170.15%

Financials

2026 *2027 *
Net sales 2.55B 2.18B 2.03B 1.88B 3.52B 244B 3.58B 24.06B 9.44B 122B 9.58B 9.37B 403B 2.87B 2.46B 2.29B 2.11B 3.96B 275B 4.03B 27.06B 10.62B 137B 10.78B 10.54B 454B
Net income 821M 703M 654M 603M 1.13B 78.57B 1.15B 7.74B 3.04B 39.29B 3.08B 3.01B 130B 974M 834M 777M 716M 1.35B 93.28B 1.37B 9.19B 3.61B 46.65B 3.66B 3.58B 154B
Net Debt -744M -638M -593M -547M -1.03B -71.28B -1.04B -7.02B -2.76B -35.65B -2.8B -2.73B -118B -1.62B -1.39B -1.29B -1.19B -2.24B -155B -2.28B -15.3B -6.01B -77.69B -6.09B -5.96B -256B
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change Volume
26-08-19 $54.39 +2.39% 2,483,760
26-08-18 $53.12 +1.53% 1,290,526
26-08-17 $52.32 +2.11% 2,372,576
26-08-14 $51.24 +1.24% 2,342,519
26-08-13 $50.61 +0.46% 1,948,740
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
53.12USD
Average target price
53.00USD
Spread / Average Target
-0.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EXEL Stock